Search results
Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?
Investor's Business Daily· 2 days agoPrevnar sales inched 2% ahead to $6.44 billion. But other key products saw downfalls. Revenue from...
The hell of drug pricing boards
Maryland Matters via Yahoo News· 1 day agoJames K. Glassman, the well-known economist whose clients have included pharmaceutical companies, makes the case against prescription drug affordability boards. The post The hell of drug pricing boards appeared first on Maryland Matters.
Where Is Amgen Headed After the Stock Surges on Obesity Drug News?
TheStreet.com· 7 days agoThe company also "tweaked" their forward guidance and the stock was raised to a fundamental...
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Zacks via Yahoo Finance· 7 days agoAmgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged"...
Siliq and cost: Reducing long-term drug costs and more
Medical News Today· 7 days agoSiliq’s cost with and without insurance can depend on several factors, such as whether Siliq has a...
3 Tried and True Dividend Stocks to Buy for Your Portfolio
InvestorPlace· 3 days agoPicking income stocks can be challenging. It varies year to year, but holding solid income stocks...
Decoding Amgen Inc (AMGN): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 6 days agoGlobal Reach and Market Share: With a presence in over 100 countries, Amgen Inc has established a significant global footprint. Its leading products,...
Will Amgen Stock Continue To See Higher Levels Driven By Its Obesity Injection?
Forbes· 2 days agoFirstly, let us look at Amgen’s stock performance. AMGN stock has shown gains of 30% from levels of...
Understanding State Prescription Drug Affordability Board Landscape in Three Infographics | JD Supra
JD Supra· 3 days agoSeveral states are considering or have enacted legislation to create prescription drug affordability boards (PDABs). PDABs powers vary by state. Colorado’s PDAB—the first in the country to begin ...
Q2 2024 EPS Estimates for Amgen Inc. Reduced by Leerink Partnrs (NASDAQ:AMGN)
ETF DAILY NEWS· 3 days agoAmgen Inc. (NASDAQ:AMGN – Free Report) – Stock analysts at Leerink Partnrs reduced their Q2 2024 earnings estimates for Amgen in a research report issued on Friday, May 3rd. Leerink Partnrs ...